A 6-week, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-group Efficacy and Safety Study of Dasotraline Versus Placebo in Subjects 6 to 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02428088 Phase 2/Phase 3 COMPLETED

This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.

Details

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	330
Start date	2015-04
Completion	2016-07

Conditions

• Attention Deficit Hyperactivity Disorder

Interventions

• Dasotraline
• Dasotraline
• Placebo Comparator

Primary outcomes

• Change from baseline at Week 6 in ADHD symptoms as measured by ADHD RS IV HV. — Baseline, 6 Weeks

Countries

United States